Australia's E-Cigarette Rules Fizzle with Only 3,500 Prescriptions in First Month

Nov.11.2024
Australia's E-Cigarette Rules Fizzle with Only 3,500 Prescriptions in First Month
Australia’s new plan to include e-cigarettes in pharmacies saw slow sales in its first month, with only 3,500 units sold. Many pharmacists are reluctant to sell e-cigarettes due to ethical concerns or complicated procedures, leading to a surge in black market e-cigarette prices to 40-60 AUD.

According to a report from Watoday on November 9, despite an estimated one million Australians using e-cigarettes, in a plan implemented by the federal government to include e-cigarettes as pharmacy products to combat the black market, only 3,500 sales were made in the first month.

 

Australia has approximately 5800 pharmacies nationwide, but data shows that thousands of them do not dispense any e-cigarette products on prescription. The federal government's initial policy analysis assumed that once illegal products are harder to obtain, about 450,000 people will seek medical e-cigarette products.

 

However, many pharmacists have stated that they are unwilling to sell e-cigarettes due to moral reasons or because the process is too cumbersome. Illegal e-cigarettes are still widely available, but prices have soared to 40 to 60 Australian dollars per device as retailers increase prices to compensate for higher penalties.

 

Last week, officials at a Senate estimates hearing stated that they currently do not track how many pharmacies are selling e-cigarettes. Chief Medical Officer Tony Lawler said that obtaining a definitive answer is actually quite difficult.

 

Health Department official Chris Bedford provided data on the sale of e-cigarette products by pharmacies following patient consultations. He stated that the total number of these sales across Australia reached 3,500, and pharmacists are able to dispense multiple e-cigarette products based on notification, leading to patients coming in and engaging in conversations.

 

Anne Ruston, the Health spokesperson for the opposition party, stated that the number of e-cigarettes sold by pharmacies last month only accounted for a small fraction of estimated e-cigarette users in Australia.

 

"We know that most pharmacists do not want to become tobacco merchants, as clearly reflected in the department's statistics."

 

Due to e-cigarette products not being included in Australia's registered therapeutic goods list, pharmacists must prescribe and sell unapproved products. This has made pharmacists cautious about supplying e-cigarettes. Data from the pharmacy industry shows that the majority of people are not willing to stock e-cigarettes, with a survey finding that 86% of pharmacies do not stock them.

 

Richard Lee, CEO of pharmaceutical company Liber Pharmaceuticals, stated that despite a slow start, the pharmacy's e-cigarette program is progressing within a reasonable range. The slow progress is partially due to the timing of the introduction of new regulations and the implementation phase. Lee expects pharmacies to gradually adapt to the new regulations and achieve significant growth within the next three to six months.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

UK HMRC Unveils Red and Yellow Transitional Vape Duty Stamps Ahead of October Tax Launch
UK HMRC Unveils Red and Yellow Transitional Vape Duty Stamps Ahead of October Tax Launch
HM Revenue & Customs (HMRC) has released sample images of the UK’s transitional vaping duty stamps, showing red and yellow versions ahead of the new Vaping Products Duty and Vaping Duty Stamps Scheme starting on October 1, 2026. Transitional stamps contain physical security features but no digital scanning function. Approved businesses may purchase them through November 30 and affix them through December 31. HMRC has not stated that the red and yellow samples represent different product categories or tax statuses.
Regulations
Sep.02
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08
Russia’s Vape Device Labeling Regime Enters Force: Registration Starts in September, Mandatory Coding in December
Russia’s Vape Device Labeling Regime Enters Force: Registration Starts in September, Mandatory Coding in December
Russia's digital labeling regime for reusable e-cigarettes and similar personal vaping devices entered its first mandatory phase in September 2026. From September 1, manufacturers, importers and other market participants must register with the national Chestny ZNAK tracking system. From December 1, newly manufactured and imported covered devices will be required to carry digital identification codes and be reported as entering circulation. Russia has also issued new operational guidance for imports, marking the transition from a voluntary pilot to phased mandatory implementation.
Sep.15
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Three R.J. Reynolds companies are seeking to intervene in a lawsuit filed by Altria subsidiaries Helix Innovations and NJOY challenging the FDA's 2021 PMTA final rule. The companies dispute how the agency uses Acceptance and Filing reviews and completeness determinations to establish when the Tobacco Control Act's 180-day decision period begins. Reynolds has also linked prolonged PMTA reviews to competition from unauthorized vaping products. The FDA, meanwhile, has been accelerating reviews and reducing its backlog.
Sep.14